Acurx Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 14.58 million compared to USD 12.09 million a year ago. Basic loss per share from continuing operations was USD 1.15 compared to USD 1.12 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.095 USD | -3.01% |
|
-5.19% | -44.55% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.55% | 34.22M | |
+18.53% | 44.87B | |
-10.09% | 37.8B | |
+40.20% | 37.61B | |
+29.49% | 31.32B | |
-8.44% | 27.4B | |
+13.10% | 26.32B | |
+43.10% | 14.07B | |
+32.92% | 12.5B | |
-6.09% | 11.23B |
- Stock Market
- Equities
- ACXP Stock
- News Acurx Pharmaceuticals, Inc.
- Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023